ABCs of NMOSD
Avsnitt

403. I-CAN, A Study of Inebilizumab in Children with AQP4+ NMOSD

ABCs of NMOSD
Dela

For this “ABCs of NMOSD” episode, Rebecca Whitney of SRNA was joined by Dr. Michael Levy. Dr. Levy gave an overview of I-CAN, a Phase 2 study of inebilizumab in children with aquaporin-4 positive neuromyelitis optica spectrum disorder or NMOSD. As one of the principal investigators for the study, he shared details about inclusion criteria and inebilizumab, brand name Uplizna™. Dr. Levy also discussed what someone can expect if they choose to participate in this trial, how participation would impact someone’s current treatment, and the timeline of this trial. Additional information is available here:

https://wearesrna.org/clinical-studies-and-trials/study-of-inebilizumab-in-pediatric-subjects-with-neuromyelitis-optica-spectrum-disorder/ 

https://clinicaltrials.gov/study/NCT05549258?term=NCT05549258&aggFilters=status:not%20rec&rank=1

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör Siegel Rare Neuroimmune Association (SRNA). Innehållet i podden är skapat av Siegel Rare Neuroimmune Association (SRNA) och inte av, eller tillsammans med, Poddtoppen.